← Cartesian Therapeutics, Inc. (RNAC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Cartesian Therapeutics, Inc. (RNAC)
Pharmaceutical Preparations · market cap $232M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
3
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Cartesian Therapeutics (RNAC) is a clinical-stage biopharma with 66 employees and a $301M market cap, built around its lead asset Descartes-08, an RNA-based cell therapy now in Phase 3 for Myasthenia Gravis (MG) with a pivotal readout expected around November 2026. The company also has Phase 2 programs in SLE and Multiple Myeloma, $118.6M in cash, and roughly 16 months of runway.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2026-12-01 (est.)Phase 2 · Descartes-08imp 7/10
- 2026-12-30 (est.)Phase 3 · Decartes-08imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Descartes-08 | Phase 2 | Systemic Lupus Erythematosus (SLE) |
| Descartes 11 | Phase 2 | Multiple Myeloma |
| Decartes-08 | Phase 3 | Myasthaenia Gravis |
Price & technical context
3-month
-27.4%
6-month
+20.0%
12-month
-26.7%
52-wk range
$5.84–$10.59
vs 50-day MA
-11.9%
vs 200-day MA
-2.7%
Realized vol
81.0%
Max drawdown
-76.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RNAC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.